Staff members at the US Federal Trade Commission said it appears Novo Nordisk A/S’ proposed bid for Metsera Inc. “may violate the procedural provisions” of the law that requires a premerger review.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback